Pathalys Pharma
Privately held: no public share price
Assets
(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
Upacicalcet(UPASITA) | Phase 3 | Calcium-sensing receptor (CaSR)Small molecule | Chronic Kidney Disease Secondary Hyperparathyroidism |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2032 (1)
February 2032 (1)
Est. primary completion 2032-02-22 · NCT07890584 · CT.gov ↗
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
23 October 2026Topline resultUpacicalcetPhase 3 PATH-1 and PATH-2 of upacicalcet in hemodialysis patients with secondary hyperparathyroidism met their primary endpoint (J Am Soc Nephrol)
Pathalys Pharma · Source ↗
Financial reports
No financial reports recorded.